- The FDA grants "conditional approval" for changes to the protocol and supporting documents for a safety trial of InVivo Therapeutics' (NVIV +10%) degradable polymer scaffold.
- The company says it will send the protocol and materials to its six sites next week "so that those sites can start their Institutional Review Board reviews and finalize contracts."
- NVIV expects "that the first site will be ready to accrue subjects in the first half of March." (PR)
InVivo Therapeutics gets conditional approval for changes to safety trial protocol
Dec 26 2013, 14:29 ET